Scholarlink

<p>A patient with multiple endocrine neoplasia 2A (MEN2A) and a suspicion of metastasized pheochromocytoma, underwent multi-molecular positron emission tomography (PET) imaging with the recently presented radiopharmaceutical [<sup>18</sup>F]-metafluorobenzylguanidine (mFBG), [<sup>68</sup>Ga]Ga-DOTA-TOC and [<sup>18</sup>F]F-dihydroxyphenylalanine (DOPA) as well as scintigraphy with [<sup>123</sup>I]-metaiodobenzylguanidine (mIBG). The methods showed different diagnostic performance, with the highest number of suspected malignant lesions detected by [<sup>18</sup>F]-mFBG-PET, and revealed insights into tumour heterogeneity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multi-molecular imaging showing tumour heterogeneity and differing diagnostic performance in a case with metastatic pheochromocytoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月1日

查看全文
  • Fredrik Hedeer,
  • Jenny Oddstig,
  • Páll Hallgrimson,
  • Katarina Fagher

摘要

A patient with multiple endocrine neoplasia 2A (MEN2A) and a suspicion of metastasized pheochromocytoma, underwent multi-molecular positron emission tomography (PET) imaging with the recently presented radiopharmaceutical [18F]-metafluorobenzylguanidine (mFBG), [68Ga]Ga-DOTA-TOC and [18F]F-dihydroxyphenylalanine (DOPA) as well as scintigraphy with [123I]-metaiodobenzylguanidine (mIBG). The methods showed different diagnostic performance, with the highest number of suspected malignant lesions detected by [18F]-mFBG-PET, and revealed insights into tumour heterogeneity.